Precigen, Inc.

NASDAQ:PGEN

0.94 (USD) • At close October 22, 2024
Bedrijfsnaam Precigen, Inc.
Symbool PGEN
Munteenheid USD
Prijs 0.937
Beurswaarde 269,645,561
Dividendpercentage 0%
52-weken bereik 0.82 - 1.93
Industrie Biotechnology
Sector Healthcare
CEO Dr. Helen Sabzevari MPH, Ph.D.
Website https://www.precigen.com

An error occurred while fetching data.

Over Precigen, Inc.

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational

Vergelijkbare Aandelen

AC Immune SA logo

AC Immune SA

ACIU

3.11 USD

ESSA Pharma Inc. logo

ESSA Pharma Inc.

EPIX

5.74 USD

Alpine Immune Sciences, Inc. logo

Alpine Immune Sciences, Inc.

ALPN

64.97 USD

Tenaya Therapeutics, Inc. logo

Tenaya Therapeutics, Inc.

TNYA

1.91 USD

AN2 Therapeutics, Inc. logo

AN2 Therapeutics, Inc.

ANTX

1.08 USD

Dyne Therapeutics, Inc. logo

Dyne Therapeutics, Inc.

DYN

33.39 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)